F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.

Dr Nessan Bermingham is a highly qualified healthcare entrepreneur, with an impressive track record of building, growing and consolidating both private and public biotech companies. Based in Boston, USA, he has over a decade of experience in the life science industry, venture capital, secondary and public markets. Most recently, Nessan co-founded Intellia Therapeutics, a company developing potentially curative genome editing treatments for people living with severe and life-threatening diseases, and led it to a successful listing on NASDAQ (NASDAQ:NTLA).

Commenting on his appointment Nessan Bermingham, Chairman of F-star said “It is an exciting time to be joining F-star’s Board. The Company is widely recognised as a leader in the bispecific antibody space and I am thrilled by the opportunities and prospects ahead of us. I am looking forward to supporting F-star in its mission to develop first-in-class therapies that have the potential to become life-changing treatments for cancer patients.”